Andersson T, Bredberg E, Lagerström P O, Naesdal J, Wilson I
Clinical Research & Development, Astra Hässle AB, Mölndal, Sweden.
Eur J Clin Pharmacol. 1998 Jul;54(5):399-404. doi: 10.1007/s002280050482.
To study, in three separate investigations, the potential interaction between omeprazole and three different non-steroidal anti-inflammatory drugs (NSAIDs; diclofenac, naproxen and piroxicam) in healthy male and female subjects.
Each investigation was an open, randomized, three-way cross-over study, in which the subjects were given omeprazole 20 mg once daily for 1 week, the NSAID in therapeutic daily doses (diclofenac 50 mg bid, naproxen 250 mg bid, or piroxicam 10 mg om), or a combination of omeprazole and each NSAID. The plasma concentrations of the NSAID as well as of omeprazole were determined on the last day of each investigation period.
None of the NSAIDs studied had any effect on the plasma concentration versus time curve (AUC) of omeprazole. It was also demonstrated that omeprazole 20 mg daily had no significant influence on the pharmacokinetics of the NSAIDs. The AUC ratio, (NSAID +omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively.
Diclofenac, naproxen, and piroxicam can be administered together with omeprazole 20 mg daily without need for dosage alteration. There was no significant change in the bioavailability of theses NSAIDs during omeprazole therapy in this study.
在三项独立研究中,探讨奥美拉唑与三种不同非甾体抗炎药(NSAIDs;双氯芬酸、萘普生和吡罗昔康)在健康男性和女性受试者中的潜在相互作用。
每项研究均为开放、随机、三交叉研究,受试者每日服用一次20 mg奥美拉唑,共1周,服用治疗剂量的NSAIDs(双氯芬酸50 mg,每日两次;萘普生250 mg,每日两次;或吡罗昔康10 mg,每日一次),或奥美拉唑与每种NSAIDs的组合。在每个研究期的最后一天测定NSAIDs以及奥美拉唑的血浆浓度。
所研究的NSAIDs均未对奥美拉唑的血浆浓度-时间曲线(AUC)产生任何影响。还表明,每日20 mg奥美拉唑对NSAIDs的药代动力学无显著影响。双氯芬酸、萘普生和吡罗昔康的AUC比值(NSAID+奥美拉唑):单独使用NSAID分别为1.11、0.99和0.99。
双氯芬酸、萘普生和吡罗昔康可与每日20 mg奥美拉唑一起给药,无需改变剂量。在本研究中,这些NSAIDs在奥美拉唑治疗期间的生物利用度无显著变化。